The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis
about
NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signalingThe retinoid X receptors and their ligandsR-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cellsRegulation of the nongenomic actions of retinoid X receptor-α by targeting the coregulator-binding sitesSulindac-Derived RXRα Modulators Inhibit Cancer Cell Growth by Binding to a Novel SiteAdvances in drug design with RXR modulatorsThe anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptorNovel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPasesDrug development against metastasis-related genes and their pathways: A rationale for cancer therapyThe aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells.Chiral Derivatives of Xanthones: Investigation of the Effect of Enantioselectivity on Inhibition of Cyclooxygenases (COX-1 and COX-2) and Binding Interaction with Human Serum Albumin.Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugsTargeting Nur77 translocation.Systems pharmacology augments drug safety surveillanceRetinoid X receptor-alpha mediates (R )-flurbiprofen's effect on the levels of Alzheimer's beta-amyloid.Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.A window-of-opportunity biomarker study of etodolac in resectable breast cancerA Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.Targeting truncated RXRα for cancer therapy.The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies.COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.NSAIDs inhibit tumorigenesis, but how?Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.A structure-based approach to retinoid X receptor-alpha inhibition.SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-Di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene.Targeting to the non-genomic activity of retinoic acid receptor-gamma by acacetin in hepatocellular carcinomaThe R-enantiomer of ketorolac delays mammary tumor development in mouse mammary tumor virus-polyoma middle T antigen (MMTV-PyMT) mice.Berberine binds RXRα to suppress β-catenin signaling in colon cancer cells.Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor.Retinoid X Receptor Antagonists
P2860
Q24319576-03F58924-D852-41D4-AA00-C27FD2920ECBQ24562747-D7C72022-522B-419D-AA85-0F5E7AF16DF9Q24669950-B62BCFB9-6734-450D-B464-BF545DB0F1B1Q27025972-C462FF1E-51B6-4E77-949A-B26000BFA800Q27682952-E4FB4ACB-87A3-43FC-9A0B-A180C65B833EQ28274388-DF1EA902-CABB-43B2-B419-AA8C4D13D67BQ28475670-55EFDC93-A158-483C-B7F4-075885B03DA5Q28550876-88FDD595-5D0B-4494-9909-F95B829D07D8Q29010479-F8A870BE-8BF9-4676-BF4D-8C6EB30B3AE9Q33695032-F310F694-5102-4809-A7BB-CCB66012C1BAQ33851532-714EC6A5-63B1-43C1-A9D8-2900D178EA99Q34234828-8B6C8176-F5EF-4129-9358-F6B5F9D18C8CQ34588195-9B8EEA55-96D2-4CFB-8D9C-456AF32E9943Q35075939-24766C6B-C2E2-4795-A8A4-C7F3C60974F1Q36107525-DDFF681D-AE8D-41AE-9DB2-EBAD7271A89AQ36187022-88E6006A-59C1-4A40-9773-46FFC4827198Q36201507-A3DEB033-DDBC-4716-9BDD-D008869F1C66Q36279606-126F41C6-8A74-47C0-AF46-AD916E4A0BA9Q36398740-D8F67999-D6EC-4D80-9FD1-10783CEA5E90Q37209932-FA93BD4C-DFB7-4232-B904-56DF4E997311Q38123175-64C83D55-38DC-403C-8519-7714B84C85ECQ38169133-DBCF30B2-BD44-422D-AC0A-436A05930EB9Q40196281-C2A9BBDB-4F9A-42AF-9548-8B6F354FEEAEQ40262487-F000AF58-974C-4E51-A0DB-3F0620452917Q40294056-BF3190D9-5EF6-447D-93C9-AB97DE7FDA66Q40440440-8D945484-3FFB-47D3-91DF-AFECF3DB78C2Q42220799-2B85E33B-4FE4-40EB-B752-3A0F6C83BBD3Q42274085-1E5A0783-73E6-4B7F-84CC-CAFF816FC416Q45324338-7FA2569C-793A-4A2E-890A-32A6DB5B672EQ47152429-EB4BC48E-E6A8-49B1-85BA-BC9382387A3EQ53343711-3329279B-344A-43E9-9A1D-91D77B0D2F65Q58789337-A642D900-1A1F-489F-B89C-35CE1D87352D
P2860
The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The R-enantiomer of the nonste ...... uces tumor-selective apoptosis
@ast
The R-enantiomer of the nonste ...... uces tumor-selective apoptosis
@en
type
label
The R-enantiomer of the nonste ...... uces tumor-selective apoptosis
@ast
The R-enantiomer of the nonste ...... uces tumor-selective apoptosis
@en
prefLabel
The R-enantiomer of the nonste ...... uces tumor-selective apoptosis
@ast
The R-enantiomer of the nonste ...... uces tumor-selective apoptosis
@en
P2093
P2860
P356
P1476
The R-enantiomer of the nonste ...... uces tumor-selective apoptosis
@en
P2093
Dennis A Carson
Desheng Lu
Howard B Cottam
Lorenzo M Leoni
Maripat Corr
Sharon Y James
Siva Kumar Kolluri
Xiao-kun Zhang
P2860
P304
P356
10.1073/PNAS.0409721102
P407
P577
2005-02-07T00:00:00Z